Pharmacokinetics and Pharmacodynamics of Nanomaterials

Chapter
Part of the Nanomedicine and Nanotoxicology book series (NANOMED)

Abstract

Nanotechnology has provided a means to generate new and more effective ways to deliver drugs into body. Nanoparticles as drug delivery system are a promising approach to obtain a drug formulation with pharmacokinetic and pharmacodynamic properties modified. Nanoparticles can be used for delivering drug in a site-specific, alleviating unwanted toxicity due to nonspecific distribution, increasing the extent of tissue-specific accumulation, improving patient compliance, and providing favorable clinical outcomes. Furthermore, the nanocarrier systems can increase the drug bioavailability, sustain drug/gene effect in the target tissue, solubilize drugs for intravascular delivery, and/or improve the stability of therapeutic agents against enzymatic degradation. However, the understanding about how the physicochemical properties of nanoparticles interact with biological systems is fundamental in order to help to design “smarter” nanostructures. The particle size, surface charge, surface modifications (e.g., targeting ligand and pegylation functionalization), and composition can influence the pharmacokinetics and pharmacodynamics of nanostructures, thus influencing in its efficacy. Particles with specific characteristics can exhibit long circulation time in the bloodstream due to delayed opsonization and increase the cellular uptake and organ accumulation, thereby enhancing the therapy effect.

Keywords

Lymphoma Serotonin Enzymatic Degradation Osteoarthritis Folic Acid 

Notes

Acknowledgment

The author acknowledges the FAPESP, INOMAT (MCT/CNPq), NanoBioss (MCTI), and Brazilian Network of Nanotoxicology (MCT/CNPq).

References

  1. Alam MI, Baboota S, Ahuja A et al (2012) Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res 46:1133–1138PubMedCrossRefGoogle Scholar
  2. Albanese A, Tang PS, Chan WCW (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16PubMedCrossRefGoogle Scholar
  3. Alexis F, Pridgen E, Molnar LK et al (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515PubMedCrossRefGoogle Scholar
  4. Arvizo RR, Miranda OR, Thompson MA et al (2010) Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 10:2543–2548PubMedCrossRefGoogle Scholar
  5. Benet LZ (1984) Pharmacokinetics: basic principles and its use as a tool in drug metabolism. In: Mitchell JR, Horning MG (eds) Drug metabolism and drug toxicity. Raven Press, New YorkGoogle Scholar
  6. Bhaskar K, Anbu J, Ravichandiran V et al (2009) Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 8:1–15CrossRefGoogle Scholar
  7. Bourne DWA (2002) Pharmacokinetics. In: Schoenwald RD (ed) Pharmacokinetics in drug discovery and development, 1st edn. CRC Press, Boca RatonGoogle Scholar
  8. Brinkhuis RP, Stojanov K, Laverman P et al (2012) Size dependent biodistribution and SPECT imaging of 111In-labeled polymersomes. Bioconjug Chem 23:958–965CrossRefGoogle Scholar
  9. Chereson R (2009) Bioavailability, bioequivalence, and drug selection. In: Makoid CM, Vuchetich PJ, Banakar UV (eds) Basic pharmacokinetics, 1st edn. Pharmaceutical Press, LondonGoogle Scholar
  10. Devalapally H, Chakilam A, Amiji MM (2007) Role of nanotechnology in pharmaceutical product development. J Pharm Sci 96:2547–2565PubMedCrossRefGoogle Scholar
  11. Dobrovolskaia MA, Aggarwal P, Hall JB et al (2008) Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5:487–495PubMedCrossRefGoogle Scholar
  12. Dobrovolskaia MA, Patri AK, Zheng J et al (2009) Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine 5:106–117PubMedCrossRefGoogle Scholar
  13. Elsaesser A, Howard CV (2012) Toxicology of nanoparticles. Adv Drug Deliv Rev 64:129–137PubMedCrossRefGoogle Scholar
  14. Ganta S, Sharma P, Paxton JW et al (2010) Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target 18:125–133PubMedCrossRefGoogle Scholar
  15. Hirn S, Semmler-Behnke M, Schleh C et al (2011) Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm 77:407–416PubMedCrossRefGoogle Scholar
  16. Huang C, Neoh KG, Kang E-T et al (2011) Surface modified superparamagnetic iron oxide nanoparticles (SPIONs) for high efficiency folate-receptor targeting with low uptake by macrophages. J Mater Chem 21:16094–16102CrossRefGoogle Scholar
  17. Jenkins AJ (2007) Pharmacokinetics: basic concepts and models. In: Chang LW (ed) Pharmacokinetics: basic concepts and models, 1st edn. CRC Press/Taylor & Francis Group, Boca RatonGoogle Scholar
  18. Jenkis AJ, Cone EJ (2007) Pharmacokinetics: drug absorption, distribution, and elimination. In: Karch SB (ed) Drug abused handbook, 2nd edn. CRC Press, Boca RatonGoogle Scholar
  19. Jiao PF, Zhou HY, Chen LX et al (2012) Cancer-targeting multifunctionalized gold nanoparticles in imaging and therapy. Curr Med Chem 18:2086–2102CrossRefGoogle Scholar
  20. Joshi M, Pathak S, Sharma S, Patraval V (2008) Design and in vivo pharmacodynamic evaluation of nanostructured lipid carriers for parenteral delivery of artemether: nanoject. Int J Pharm 364:119–126PubMedCrossRefGoogle Scholar
  21. Kularatne SA, Low PS (2010) Targeting of nanoparticles: folate receptor. Methods Mol Biol 624:249–265PubMedCrossRefGoogle Scholar
  22. Litzinger DC, Buiting AMJ, Vanrooijen N, Huang L (1994) Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim Biophys Acta 1190:99–107PubMedCrossRefGoogle Scholar
  23. Marcato PD, Durán N (2008) New aspects of nanopharmaceutical delivery systems. J Nanosci Nanotechnol 8:2216–2229PubMedCrossRefGoogle Scholar
  24. Mohanraj VJ, Chen Y (2006) Nanoparticles: a review. Trop J Pharm Res 5:561–573Google Scholar
  25. Slowing I, Trewyn BG, Lin VSY (2006) Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc 128:14792–14793PubMedCrossRefGoogle Scholar
  26. Thorek DLJ, Tsourkas A (2008) Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 29:3583–3590PubMedCrossRefGoogle Scholar
  27. Wang X, Li J, Wang Y et al (2011) A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 5:6184–6194PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Faculty of Pharmaceutical Sciences of Riberão PretoUniversidade de São PauloRibeirão PretoBrazil

Personalised recommendations